CS 1036

Drug Profile

CS 1036

Alternative Names: CS-1036

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 26 May 2011 Discontinued - Phase-II for Diabetes mellitus in Asia (PO)
  • 26 May 2011 Discontinued - Phase-II for Diabetes mellitus in Japan (PO)
  • 21 May 2010 Phase-II clinical trials in Diabetes mellitus in Asia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top